CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

Positive
AI Analysis

Summary

BMO Capital raised its price target on AbbVie to $300 from $258 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.60
price_targetanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on July 13, 2026 2:13 PM

Read Original